肿瘤标记物Cytokeratin19诊断肺癌的临床价值

Clinical Value of a Cancer Marker Cytokeratin 19 for Diagnosis of Lung Cancer

目的：探讨细胞角蛋白 １９（ Ｃ Ｋ１９）作为肺癌指标的临床价值。方法：应用 Ｃｅｎｔｏｃｏｒ Ｃ Ｙ Ｆ Ｒ Ａ２１１ 放射免疫分析药盒测定肺癌病人血清细胞角蛋白１９（ Ｃ Ｋ１９）的数值。结果：健康人 Ｃ Ｋ１９ 的平均值为 ０．６７ ｎｇ／ｍ ｌ，肺腺癌（Ⅲ、Ⅳ期） Ｃ Ｋ１９ 的阳性率为４１．７％ ，肺鳞状上皮癌（Ⅲ、Ⅳ期）为６９．２％ ，大细胞肺癌为２５．０％ ，小细胞肺癌为 ３３．３％ 。 Ｃ Ｋ１９ 比 Ｓ Ｃ Ｃ抗原具有较高的阳性率。结论： Ｃ Ｋ１９ 对肺鳞状上皮癌具有较高的诊断价值。

Objective:This paper was designed to value the clinical significance of a lung cancer marker,cytokeratin 19(CK19).Methods:With the aid of Centocor CYFRA 21 1 RIA kit, wedetected the serum CK19 in patients with lung cancer.With the aid of Centocor CYFRA 21 1 RIA kit, wedetected the serum CK19 in patients with lung cancer.Results:The mean value of CK19 in normal people was 0.67 ng/ml. The positive rate of CK19 was 41.7%, in pulmonary adenocarcinoma (Ⅲ、Ⅳ phase) 69.2% in squamous cell carcinoma(Ⅲ、Ⅳ phase),25.0% in large cell carcinoma of lung,and 33.3% in small cell carcinoma. The positive rate of CK19 was higher than that of SCC antigen. The mean value of CK19 in normal people was 0.67 ng/ml. The positive rate of CK19 was 41.7%, in pulmonary adenocarcinoma (Ⅲ、Ⅳ phase) 69.2% in squamous cell carcinoma(Ⅲ、Ⅳ phase),25.0% in large cell carcinoma of lung,and 33.3% in small cell carcinoma. The positive rate of CK19 was higher than that of SCC antigen. Conclusion:CK19 was of significantly dcagnostic value for squamous epithelioma.